Agency officials said during a meeting in Geneva that they hope to drive down insulin prices by encouraging generic drugmakers to enter the market and increase competition.
“The amount of insulin available to treat diabetes is too low, the prices are too high, so we need to do something,” said Emer Cooke, the WHO director of regulation of medicines and other health technologies.
The insulin market is currently dominated by three drugmakers — Eli Lilly, Novo Nordisk and Sanofi — all of which have steadily increased prices over the last two decades, according to The New York Times.
The prequalification program will allow United Nations agencies and medical charities like Doctors Without Borders to buy approved generic versions of insulin. The inspection and approval process currently takes about nine months.
UNICEF, the UN Development Program and Doctors Without Borders have all said they would likely buy insulin from the WHO program, according to The New York Times.
Ms. Cooke said cheaper insulin products could be on the market within two years.
However, the program likely won’t immediately affect insulin prices in the U.S., as the application process for FDA approval is prohibitively expensive for many small drugmakers, according to The New York Times.
Read the full article here.
More articles on pharmacy:
Endo CEO to retire
Trump administration sues Gilead
CVS to close 22 ‘underperforming’ stores
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.